Semaglutide: The Complete Guide (Ozempic, Wegovy & Rybelsus)

Semaglutide is a once-weekly (or once-daily, by pill) medicine that lowers blood sugar and reduces appetite by copying a natural gut hormone called GLP-1. You have almost certainly heard one of its brand names: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight loss. Under the hood, all three are the same molecule, just packaged and dosed for different jobs.

This is the high-level hub guide to the whole compound: what semaglutide actually is, how it works in your body, what it is approved to treat, a dosing overview, the side effects to know, the kind of results seen in trials, its safety and legal status, and how people obtain it. Where a topic deserves its own deep dive, such as the full dosing chart, the side-effect playbook, or the semaglutide-versus-tirzepatide comparison, we keep it short here and point you to a dedicated guide. The goal is one clear map of the entire subject. If you're still deciding what to use, our roundup of the best peptides for weight loss sets semaglutide alongside the alternatives.

Key Takeaways

• Semaglutide is a GLP-1 receptor agonist that mimics the gut hormone GLP-1 to boost insulin when blood sugar is high, slow stomach emptying, and reduce appetite (StatPearls / NCBI, 2024).
• It is FDA-approved as three brands: Ozempic (type 2 diabetes, plus heart and kidney risk reduction), Wegovy (chronic weight management, plus cardiovascular risk reduction), and Rybelsus (oral, type 2 diabetes) (FDA, Drugs@FDA).
• Weight-loss results are large. In the STEP 1 trial, adults on semaglutide 2.4 mg lost an average of 14.9% of body weight at 68 weeks, versus 2.4% on placebo (NEJM, 2021).
• It protects the heart. In SELECT, semaglutide 2.4 mg cut major cardiovascular events by about 20% in people with obesity and heart disease but no diabetes (NEJM, 2023).
• Side effects are mostly digestive (nausea, diarrhea, constipation) and are managed by slow dose titration; there is a boxed warning for thyroid C-cell tumors (Mayo Clinic, 2026).
• Dosing is always titrated up slowly. The injectable line starts at 0.25 mg weekly; maintenance ranges run to 2 mg (Ozempic) or 2.4 mg (Wegovy). Detailed schedules belong to the semaglutide dosing chart guide.

What is semaglutide?

Semaglutide is a lab-made copy of a natural hormone, designed to control blood sugar and appetite, and it is the active drug inside Ozempic, Wegovy, and Rybelsus. It belongs to a drug class called GLP-1 receptor agonists. In plain terms, it is a peptide, a short chain of amino acids, engineered to act like the gut hormone GLP-1 but to last far longer in the body.

The "longer-lasting" part is the clever bit. Natural GLP-1 is broken down within minutes. Semaglutide is modified so it resists that breakdown and binds to blood proteins, which stretches its half-life to about one week (StatPearls / NCBI, 2024). That single fact is why the injectable versions are taken just once a week. Structurally, semaglutide shares about 94% homology with human GLP-1, so the body's GLP-1 receptors recognize it almost as the real thing (StatPearls / NCBI, 2024).

Semaglutide was developed by Novo Nordisk and first approved in 2017. It is one of the most consequential drugs of the decade, reshaping how medicine treats both type 2 diabetes and obesity. For the broader chemistry of what peptides are and how they signal, see what peptides are and how peptides work in the body.

Citation capsule. Semaglutide is a GLP-1 receptor agonist with roughly 94% structural homology to human GLP-1 and an elimination half-life of about one week, which allows once-weekly subcutaneous dosing. It is the active ingredient in Ozempic, Wegovy, and Rybelsus. Source: StatPearls (NCBI Bookshelf), "Semaglutide," 2024.

How does semaglutide work in your body?

Semaglutide works by mimicking GLP-1, a hormone your gut releases after eating, which tells your body to release insulin, stop making excess sugar, slow your stomach, and feel full. The result is steadier blood sugar and a smaller appetite, without relying on willpower.

There are four linked effects worth knowing. First, when blood sugar is high, semaglutide stimulates the pancreas to release insulin and suppresses glucagon, the hormone that raises blood sugar; because this is glucose-dependent, it carries a low risk of hypoglycemia on its own (StatPearls / NCBI, 2024). Second, it slows gastric emptying, so food leaves the stomach more gradually and you feel full longer. Third, it acts on appetite centers in the brain (the hypothalamus), reducing hunger and food cravings. Fourth, by curbing intake and improving metabolic signals, it drives meaningful weight loss over time.

This is why the same molecule treats two different problems. For someone with type 2 diabetes, the insulin and glucagon effects dominate the benefit. For someone using it for weight, the appetite and gastric-emptying effects do the heavy lifting. The mechanism is shared; the framing changes with the goal. The deeper receptor-and-signaling science lives in our how peptides work guide so this page stays an overview.

What is semaglutide used for?

Semaglutide is FDA-approved to treat type 2 diabetes, to drive chronic weight management, and to reduce the risk of heart attack and stroke, with the exact approved use depending on the brand. It is not approved as a casual or cosmetic slimming aid; every approved use is a defined medical indication.

The approved indications break down by brand:

• Ozempic (injectable): type 2 diabetes blood-sugar control; reducing the risk of major cardiovascular events in adults with type 2 diabetes and heart disease; and slowing chronic kidney disease progression in type 2 diabetes (FDA, Drugs@FDA).
• Wegovy (injectable, and now an oral form): chronic weight management in adults and adolescents 12+ with obesity or overweight plus a weight-related condition; reducing cardiovascular event risk in adults with established heart disease and obesity or overweight; and non-cirrhotic MASH (a fatty-liver condition) (FDA, Drugs@FDA).
• Rybelsus (oral tablet): type 2 diabetes blood-sugar control, plus cardiovascular risk reduction (FDA, Drugs@FDA).

Beyond the label, semaglutide is being studied for additional conditions, and clinicians sometimes prescribe approved drugs off-label at their discretion. But the responsible framing is simple: the strong evidence sits behind the approved uses above.

Ozempic vs Wegovy vs Rybelsus: what is the difference?

They are all semaglutide, but they differ in form, dose, and what they are approved to treat: Ozempic and Rybelsus target diabetes, while Wegovy targets weight, and Rybelsus is the pill. Choosing between them is a clinical decision, not a shopping one, because insurance, indication, and dose ceiling all differ.

Here is the high-level comparison. A full head-to-head, including cost and access, is its own guide.

The oral story is changing fast. Rybelsus has been the daily tablet for diabetes since 2019, and in December 2025 the FDA approved a higher-dose oral semaglutide 25 mg (Wegovy) as the first oral GLP-1 for chronic weight management (NPR, 2025). Oral semaglutide must be taken on an empty stomach with a small sip of water, because the peptide is otherwise destroyed in the gut. For the full brand-by-brand breakdown, see Ozempic vs Wegovy vs Rybelsus comparison. And if you're weighing semaglutide against newer molecules, we line it up head-to-head with the triple agonist in semaglutide vs retatrutide, against the amylin co-agonist in cagrilintide vs semaglutide, and against the oral GLP-1 in orforglipron vs semaglutide.

Semaglutide dosing: a high-level overview

Semaglutide is always started low and increased slowly over weeks (called titration) to limit nausea, with the exact schedule set by your clinician and the brand. This overview gives the trial-and-label ranges for orientation; it is not a protocol to follow on your own.

The injectable line follows a familiar pattern. Treatment typically begins at 0.25 mg once weekly for four weeks (a starter dose that is not yet therapeutic), then steps up roughly every four weeks as tolerated. Ozempic maintenance commonly lands at 0.5 mg, 1 mg, or 2 mg weekly; Wegovy titrates to a target maintenance of 2.4 mg weekly, usually reached around week 16 (StatPearls / NCBI, 2024). Oral Rybelsus runs on a separate scale of 3 mg, 7 mg, and 14 mg once daily (StatPearls / NCBI, 2024).

A few orientation points, framed as label/trial figures and not advice:

• Why so slow? The step-up exists almost entirely to let your gut adjust and to blunt nausea. Rushing the titration is the most common reason people feel awful.
• The starter dose is not the working dose. 0.25 mg weekly is there to acclimate the body; it is not expected to deliver full results.
• Higher is not automatically better. The maintenance dose is whatever controls the condition at the lowest effective level your clinician chooses.

We deliberately keep the numbers high-level here. The week-by-week titration calendar, dose-conversion details, and what to do about missed or skipped doses live in the dedicated semaglutide dosing chart guide. Anything involving drawing from a vial belongs to the peptide injection guide.

What are the side effects of semaglutide?

Most semaglutide side effects are gastrointestinal, such as nausea, vomiting, diarrhea, and constipation, and they tend to ease as the body adjusts; a smaller set of serious risks requires medical attention. The trade-off profile is well characterized from large trials and the FDA label.

The common effects are digestive and dose-related. In the Wegovy obesity trials, nausea was reported by roughly 44% of participants, making it the single most common complaint (StatPearls / NCBI, 2024). Vomiting, diarrhea, constipation, abdominal pain, and fatigue are also frequent. These typically appear after a dose increase and fade over days to weeks, which is exactly why titration is slow.

The serious, less-common risks are the ones to understand before starting:

• Thyroid C-cell tumors (boxed warning). Animal studies showed thyroid tumors; semaglutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome (Mayo Clinic, 2026).
• Pancreatitis, gallbladder disease, and acute kidney injury (the latter often via dehydration from vomiting or diarrhea) (StatPearls / NCBI, 2024).
• Diabetic retinopathy changes in some people with diabetes, plus rare allergic reactions.

This is the overview. The full side-effect playbook, including how clinicians manage nausea and who should avoid the drug entirely, is covered in the dedicated semaglutide side effects guide.

What results can you expect from semaglutide?

For weight, semaglutide produces large average losses, around 15% of body weight at the 2.4 mg dose in trials, and for diabetes it meaningfully lowers blood sugar and even cuts heart-attack and stroke risk. Results build over months, not days, and depend on dose and consistency.

The headline weight number comes from the STEP 1 trial. Adults with obesity who took semaglutide 2.4 mg weekly plus lifestyle support lost a mean of 14.9% of body weight at 68 weeks, compared with 2.4% on placebo (NEJM, "Once-Weekly Semaglutide in Adults with Overweight or Obesity," 2021). In that trial, about 86% of participants lost at least 5% of their weight, and roughly half lost 15% or more (NEJM, 2021).

The cardiovascular results are just as important. In the SELECT trial of more than 17,600 people with obesity and established heart disease but no diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events by about 20% versus placebo (NEJM, "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes," 2023). And in the earlier SUSTAIN 6 diabetes trial, semaglutide cut the risk of a first major cardiovascular event with a hazard ratio of 0.74 (NEJM, "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes," 2016).

A realistic expectation: results are an average, individuals vary widely, and weight tends to return if the drug is stopped without other changes. For the timeline and what before-and-after really looks like, see peptide before and after expectations.

How long does semaglutide stay in your system?

Semaglutide has a half-life of about one week, so it takes roughly five weeks to clear almost completely after the last dose and about four to five weeks to reach steady levels when starting. That long half-life is the whole reason the injection is weekly rather than daily.

In practical terms, a half-life of about 7 days means the drug leaves the body gradually: after one week half remains, after two weeks a quarter, and so on, so it is largely gone roughly five weeks after the final injection (StatPearls / NCBI, 2024). The same math works in reverse when starting, which is why people often do not feel the full effect of a new dose for about a month, and why titration steps are spaced four weeks apart. Appetite and side effects both track this slow build-up and wind-down.

What does our community usage data show?

Across the ProtocolPlus community, semaglutide is one of the most-tracked compounds, and people typically finish a reconstituted vial in about three to four weeks, which lines up with the once-weekly dosing schedule. These are usage-pattern figures from our app, labeled as community signal, not a clinical or stability claim.

Within our anonymized tracking data, semaglutide accounts for a large share of activity: 38,900 logged doses from 6,224 tracking users, drawn from a global window of 27,272 unique trackers and 230,268 logged doses (data window September 2024 to June 2026). The median reconstituted vial in our community runs about 26 days from first to last logged dose. That clusters right around a 3-to-4-week window, consistent with weekly dosing out of a multi-dose vial. As with all our app data, these numbers describe how people use the compound, not how long it is chemically stable.

Is semaglutide safe?

Semaglutide has a large, well-studied safety record at its approved doses, but it is a serious prescription drug with real contraindications and a boxed warning, not a casual supplement. Safety always depends on the right patient, the right dose, and medical supervision.

The reassuring side: semaglutide has been tested in tens of thousands of people across the SUSTAIN, STEP, and SELECT programs, and it not only controls disease but reduces cardiovascular events. The cautious side: it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, and it should be used carefully in people with a history of pancreatitis, severe gastrointestinal disease, or certain eye disease (Mayo Clinic, 2026). It is not recommended in pregnancy, and it is not for type 1 diabetes.

One safety issue is specific to where you get the drug. Compounded or "research" semaglutide sold outside the regular pharmacy supply chain is not verified by the FDA for quality, dose accuracy, or sterility, and the agency has warned that some compounders used different salt forms that are not the same approved active ingredient (Healthline, 2024). If you cannot confirm what is in the vial, you cannot confirm it is safe. Learn what real verification looks like in how to vet peptide quality.

Our take: "Is semaglutide safe?" has no one-word answer. Pharmacy-grade semaglutide, prescribed and monitored, has one of the strongest safety datasets in modern metabolic medicine. An unverified vial from an unregulated seller is a completely different risk, even though the molecule is named the same. The source matters as much as the substance.

Is semaglutide legal, and how do you get it?

Semaglutide is fully legal as an FDA-approved prescription medicine in the United States, obtained through a licensed clinician and a pharmacy; buying unapproved "research" versions is a legal and safety gray zone. There is a clear, legitimate path, and there is a risky shortcut.

The legitimate path is straightforward: a licensed clinician (in person or via a reputable telehealth service) evaluates whether you are a candidate, writes a prescription for Ozempic, Wegovy, or Rybelsus, and a pharmacy dispenses the genuine, quality-controlled product. This is the only route that guarantees you are getting verified semaglutide at an accurate dose.

The gray-zone path is the unregulated market: vials labeled "for research use only," compounded products from outside the standard supply chain, or overseas sellers. During the 2022 to 2024 shortages, compounded semaglutide became widespread, but the FDA declared the shortage resolved, which limits when compounding is permitted (FDA, "Declaratory Order: Resolution of Shortages of Semaglutide," 2025). Products sold as research chemicals are not legal for human use and are not quality-verified. For the broader rules on peptide legality, see are peptides legal.

How is semaglutide taken?

The injectable forms are given as a small once-weekly shot under the skin, while Rybelsus is a daily tablet taken on an empty stomach; the brand-name pens are designed to make injecting simple. Technique matters less with a pre-filled pen than with a vial you draw yourself.

For the once-weekly injection, the basics look like this. This is an orientation, not instructions to self-treat outside medical guidance:

1. Pick a consistent day each week; the long half-life means timing is forgiving but routine helps.
2. Rotate the injection site among the abdomen, thigh, or upper arm to protect the skin.
3. Inject subcutaneously (into the fat just under the skin), not into muscle.
4. Follow the titration schedule your clinician set, increasing only when told to.
5. Store it correctly, refrigerated before first use and per the label afterward.

Oral Rybelsus has its own rule that is easy to get wrong: take it on an empty stomach with no more than about 4 ounces (120 mL) of plain water, then wait at least 30 minutes before eating, drinking anything else, or taking other medicines (Healio, 2026). That window is what lets the peptide survive long enough to be absorbed. The full injection walkthrough, including reconstitution if you ever handle a vial, is in our peptide injection guide.

Frequently Asked Questions

The bottom line

Semaglutide is a single molecule with an outsized footprint. As Ozempic and Rybelsus it controls type 2 diabetes and protects the heart and kidneys; as Wegovy it drives weight loss large enough to cut cardiovascular events. It works by mimicking the gut hormone GLP-1, lasts about a week in the body so it can be dosed weekly, and is started low and raised slowly to keep the mostly digestive side effects manageable.

If you take away one idea, make it this: semaglutide's benefits and its safety both depend on context. Pharmacy-grade, prescribed, and monitored, it is one of the best-studied metabolic drugs available. Unverified, unregulated, or rushed, it is a different and riskier proposition. From here, the natural next steps are the detailed dosing chart, the side-effect playbook, and the brand comparison. And for anything you might consider, talk to a qualified clinician first.

Sources

• Aroda VR, et al. "Semaglutide." StatPearls (NCBI Bookshelf), 2024. Retrieved 2026-06-15. https://www.ncbi.nlm.nih.gov/books/NBK603723/
• Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021 (STEP 1). Retrieved 2026-06-15. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine, 2023 (SELECT). Retrieved 2026-06-15. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
• Marso SP, Bain SC, Consoli A, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." New England Journal of Medicine, 2016 (SUSTAIN 6). Retrieved 2026-06-15. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
• U.S. Food and Drug Administration. "Drugs@FDA: FDA-Approved Drugs" (Ozempic, Wegovy, Rybelsus approval records). Retrieved 2026-06-15. https://www.accessdata.fda.gov/scripts/cder/daf/
• U.S. Food and Drug Administration. "Declaratory Order: Resolution of Shortages of Semaglutide Injection Products." 2025. Retrieved 2026-06-15. https://www.fda.gov/media/185526/download
• Mayo Clinic. "Semaglutide (subcutaneous route): Side effects & dosage." 2026. Retrieved 2026-06-15. https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/description/drg-20406730
• Healio. "Semaglutide: Uses, Side Effects & Dosage." 2026. Retrieved 2026-06-15. https://www.healio.com/clinical-guidance/drugs/semaglutide
• Healthline. "Is Compounded Semaglutide Safe?" 2024. Retrieved 2026-06-15. https://www.healthline.com/health/is-compounded-semaglutide-safe
• NPR. "U.S. regulators approve Wegovy pill for weight loss." 2025. Retrieved 2026-06-15. https://www.npr.org/2025/12/23/g-s1-103424/us-approve-pill-for-weight-loss
• American College of Cardiology. "STEP 1: Semaglutide Treatment Effect in People With Obesity." 2021. Retrieved 2026-06-15. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2021/02/18/19/23/STEP-1